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ABSTRACT
Introduction:  Non-epithelial  breast  malignancies  include  primary  lymphomas,  sarcomas,  haematological  malignancies, 
melanomas as well as secondary metastases to the breast. They account for less than 1% of all breast tumours. The demographics 
and clinical features are similar to epithelial breast cancers but the prognosis and management options are often very different. 
Most reported series are small with limited follow-up. The main aim of this study was to review our experience for these 
malignancies and to compare this with the published literature.
Methods: A 14-year retrospective review of all breast resection specimens was completed in the Antrim Area Hospital Cancer 
Unit. Clinical records of patients diagnosed with non-epithelial breast malignancies were then reviewed for data regarding 
patient demographics, clinical presentation, pre-operative investigations, operative findings and outcome. Pathology reports 
were examined carefully for tumour type, location and for evidence of lymphovascular spread. This data was compared with 
the available literature.
Results: Nineteen (F = 16) patients were found to have non-epithelial breast malignancies between April 1994 and August 2007. 
Mean age was 61.6 years (range 25-86). 17 patients (89.5%) presented with a palpable lump, mastalgia or skin change, while 2 
(10.5%) patients’ tumours were detected through screening. The histological types of non-epithelial malignancies were as follows: 
lymphoma (n = 8; M = 1 and F = 7, mean age: 68.5 range 52-86), sarcoma (n = 5; M = 1 and F = 4, mean age 56.4 range 29-69), 
malignant melanoma (n = 3; M = 1 and F = 2, mean age 54.3 range 25-70), multiple myeloma (n = 1; F, 71), metastatic renal 
cell carcinoma (n = 1; F, 63) and metastatic carcinoid tumour (n = 1; F, 52). The mean follow-up was 1541 days (32-4589 days). 
Nine patients were alive at the end of follow-up. Only 1 of 11 deaths was not directly related to the malignancy.  The average 
time from surgery to death was 798.5 days (range 32-3248 days).  
Conclusion: Non-epithelial breast malignancies are rare cancers with significant mortality rates. Correct diagnosis and avoidance 
of inappropriate therapies requires a comprehensive triple assessment and a multidisciplinary management approach. 
Keywords: Breast, lymphoma, melanoma, myeloma, renal, neoplasm, sarcoma.  
INTRODUCTION
Breast cancer is one of the most common cancers in Northern 
Ireland  with  an  annual  incidence  of  approximately  1000 
newly diagnosed cases and over 300 deaths1. Between 1993 
and 2003, the incidence of breast cancer in Northern Ireland 
increased by an average of 1.1% per year - equivalent to 20 
cases2. Worldwide, more than a million women are diagnosed 
with breast cancer every year, accounting for 10% of all new 
cancers and 23% of all female cancer cases3.
Carcinomas  such  as  ductal  and  lobular  carcinoma  are 
responsible  for  over  95%  of  all  breast  cancers4.  Non-
epithelial breast malignancies include haematogenous and 
non-epithelial  tumours  such  as  lymphoma,  sarcoma  and 
metastatic breast neoplasms of neuroendocrine, renal or skin 
origins5. Less than 1% of breast tumours are non-epithelial 
cancers and between 0.5% and 2% are metastatic deposits5,6. 
Much less is known about these non-epithelial malignancies 
of the breast compared with epithelial breast cancers. Most 
reported series are small with limited follow-up data. Young 
et  al  investigated  363,801  patients  with  newly  diagnosed 
malignant breast cancers between 1994 and 1998 and found 
that 1401 (0.4%) were non-epithelial in origin5. The majority 
of these were sarcomas. A further 613 tumours were classified 
as  haematopoietic  cancers  and  were  mostly  lymphomas. 
The  presentation,  demographics  and  clinical  features  of 
non-epithelial and epithelial breast malignancies are similar. 
However, the prognosis and management options are often 
very  different.  Our  objective  was  to  review  all  patients 
diagnosed  with  non-epithelial  malignancies  of  the  breast 
and to compare our clinical experience with the published 
evidence.© The Ulster Medical Society, 2009.
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METHODS
A  14-year  retrospective  histopathological  review  of  all 
breast  resection  specimens  was  completed  in  the Antrim 
Area  Hospital  Cancer  Unit.  Clinical  records  of  patients 
diagnosed with non-epithelial breast malignancies were then 
reviewed for data regarding patient demographics, clinical 
presentation, pre-operative investigations, operative findings, 
treatment and outcome. Investigative modalities were graded 
in a standardised manner where grade 1 corresponded to 
normal appearance, grade 2 benign disease, grade 3 atypical 
or indeterminate but probably benign, grade 4 suspicious 
of  malignancy  and  grade  5  consistent  with  malignancy. 
Pathology reports were examined carefully for tumour type, 
location and for evidence of lymphovascular spread. 
We differentiated primary breast sarcoma from cystosarcoma 
phyllodes7, therefore, we excluded patients with malignant 
phyllodes tumours. In the absence of adequate clinical follow-
up data in the hospital records, a postal questionnaire was sent 
to each patient’s General Practitioner. All aspects of adjuvant 
therapies were documented. 
RESULTS
Approximately 3900 patients had a pathological diagnosis 
of  breast  cancer  between  April  1994  and  August  2007. 
Nineteen (F = 16) were found to have non-mammary breast 
malignancies (Table I). Mean age was 61.6 years (range 25-
86). Seventeen patients presented to a symptomatic breast 
out-patient clinic with either a history of a breast lump, skin 
change or mastalgia. Two patients were referred to the breast 
clinic for further follow-up because of a screening detected 
abnormality on mammography. 
The histological types of non-epithelial malignancies were as 
follows: lymphoma (n = 8, 0.21% of all breast malignancies), 
sarcoma (n = 5, 0.13%), malignant melanoma (n = 3, 0.07%), 
multiple  myeloma  (n  =  1,  0.03%),  metastatic  renal  cell 
carcinoma (n = 1, 0.03%) and metastatic carcinoid tumour (n 
= 1, 0.03%) (Figures 1 – 5). The mean follow-up was 1541 
days (32-4589 days). Nine patients were alive at the end of 
follow-up. Only 1 of 11 deaths was not disease related. The 
mean time from surgery to death was 798.5 days (range 32-
3248 days).  
Lymphoma
Five female patients (patients 1-5 from table I) were diagnosed 
with a primary breast lymphoma (mean age 70.4 years, range 
59-86 years). Four patients presented with a breast lump. An 
asymptomatic patient was referred from the breast screening 
unit. All patients had unilateral disease (left = 2, right = 
3). The mean duration of symptoms was 37.3 days (range 
7-93  days). Three  patients  had  mammography  performed 
(Grade: M3 = 1 from screening, M4 = 2). One patient had 
an  ultrasound  scan  (Grade:  U3).  Four  patients  had  FNA 
cytology performed (Grade: C1 = 1, C3 = 3). The lymphoma 
diagnosis was made following core biopsy in two cases and 
excision biopsy in three cases. Pathological analysis identified 
primary diffuse large B-cell non-Hodgkins lymphoma (NHL) 
(n = 4) (Figure 1) and a primary MALT-type lymphoma (n = 
1). Four patients had chemotherapy with the CHOP regimen 
(cyclophosphamide, doxorubicin HCl, vincristine (Oncovin), 
prednisolone).  There  is  no  documentation  of  whether 
chemotherapy was administered in patients 2 and 4 who both 
had advanced metastatic disease from their primary breast 
lymphoma. Patient 3 underwent subsequent radiotherapy for 
metastatic axillary node disease. Three patients are currently 
still  alive.  Patient  5  has  had  several  recurrences  and  has 
had further courses of chemotherapy for lung involvement. 
Patient 1 also required a further course of chemotherapy for 
recurrence. Patients 2 and 4 died from metastatic spread of 
their primary breast lymphoma where the mean time from 
diagnosis to death was 3248 and 32 days respectively.  
Three patients (patients 6-8 from table I, male = 1) were 
Fig 1. High-grade non-Hodgkin’s breast lymphoma (haemotoxylin 
and eosin x 200) (Inset CD45 staining). This field shows large 
blast-like lymphoid cells with conspicuous background apoptosis, 
features in keeping with a diffuse large B-cell lymphoma.
Fig 2. Breast sarcoma (H&E x 200). This field shows large 
spindle shaped cells with nuclear pleomorphism and eosinophilic 
cytoplasm. There is no differentiation which would indicate the 
cell of origin.© The Ulster Medical Society, 2009.
Non-epithelial malignancies and metastatic tumours of the breast 107
www.ums.ac.uk
diagnosed  with  a  metastatic  breast  lymphoma  from  a 
remote primary lesion (mean age 65.3 years, range 52-79 
years). All three patients presented with a breast lump while 
one  complained  of  mastalgia. All  patients  had  unilateral 
disease (left = 2, right = 1). The mean duration of symptoms 
was  186.0  days  (range  7-365  days).  One  patient  had 
mammography performed (Grade: M4). One patient had an 
ultrasound scan (Grade: U4). Two patients had FNA cytology 
performed (Grade: C2 = 1, C5 = 1). The lymphoma diagnosis 
was made following core biopsy in one case and excision 
biopsy  in  two  cases.  Pathological  analysis  identified  the 
presence of metastatic B-cell NHL in all three patients. Two 
patients had chemotherapy with the CHOP regimen. Patient 
6 underwent simple mastectomy without adjuvant therapy. 
Patient 8 underwent subsequent radiotherapy to treat cerebral 
metastases. Unfortunately all three patients have died where 
the mean time from diagnosis to death was 775, 1045 and 133 
days for patients 6-8 respectively.   
Sarcoma
Three patients (patients 9-11 from table I, male = 1) had 
primary  breast  sarcomas  (fig  2)  with  an  average  age  of 
50.7  years  (range  29-65  years). All  patients  presented  to 
our symptomatic breast clinic with either a lump (n = 2) 
and/or mastalgia (n = 2) (left  = 2, right = 1). The mean 
duration of symptoms was 192 days (range 31-365 days). 
Patients 9 and 10 had palpable masses whereas patient 11 
had minimal localised thickening only. Patients 9 and 10 had 
positive mammograms (M4 = 2) while patients 10 (U4) and 
11 (U1) had ultrasound assessments. Fine needle aspiration 
was positive in patient 9 (C5) but insufficient in patient 11 
(C1). Patient 9 underwent simple mastectomy and axillary 
node  clearance  for  a  primary  rhabdomyosarcoma  where 
immunohistochemical labeling was positive for actin (smooth 
muscle) and negative for epithelial markers. Despite adjuvant 
chemo- and radiotherapy, she died 553-days post-surgery. 
Patient 10 had a simple mastectomy for dermatofibrosarcoma 
protruberans  and  remains  well  380-days  later.  Although 
ultrasound,  magnetic  resonance  imaging  (MRI)  and  FNA 
cytology  investigations  were  normal  patient  11,  further 
investigation  was  arranged  due  to  a  persistent  clinical 
suspicion  of  a  possible  lesion. A  subsequent  ultrasound-
guided excisional biopsy demonstrated an angiosarcoma. She 
proceeded to simple mastectomy with adjuvant radiotherapy 
followed by delayed breast reconstruction one-year later. She 
remains well 1415 days following her initial breast surgery. 
Two  female  patients  (patients  12-13  from  table  I),  aged 
69 and 61, were diagnosed with metastatic sarcomas from 
distant primary neoplasms. Patient 12 had a previous primary 
thigh liposarcoma resection while patient 13 had a previous 
excision of a primary retroperitoneal leiomyosarcoma. Both 
of these patients presented with painless lumps in the left 
breast. The mean duration of symptoms was 5 days (range 3-7 
days). Patient 12 had a positive mammogram (M4) and FNA 
(C5) with confirmation of sarcoma following core biopsy 
with vimentin positive immunohistochemical labeling while 
other epithelial, neural (S100) and muscle (actin and desmin) 
markers were negative. She was treated with palliative chemo- 
and radiotherapy and died 679 days later. Patient 12 had a 
positive mammogram (M4) and FNA (C5) with confirmation 
of sarcoma following core biopsy. Patient 12 did not undergo 
surgery  as  staging  investigations  had  shown  widespread 
metastatic disease. She was treated with palliative chemo- and 
radiotherapy and died 679 days later. Patient 13 proceeded 
directly to lumpectomy. She refused adjuvant therapy and 
remains well 2980-days following lumpectomy and has had 
further surgery for abdominal wall recurrences in the interim. 
Malignant melanoma
Three patients (patients 14-16 from table I, male = 1) had a 
malignant melanoma with an average age of 54.3 years (25-70 
years). These patients presented with an enlarging naevus on 
the right breast (patient 14), a superficial nodule on the left 
breast (patient 15) and a right-sided breast lump (patient 16). 
The mean duration of symptoms was 699 days (range 93-1825 
days). Patient 14 had palpable axillary nodes and proceeded 
directly to excision biopsy with ANC. A mastectomy was 
subsequently required due to involved breast margins from 
deeper infiltration of the primary melanoma. Although further 
adjuvant treatment was declined, the patient remains disease-
free. Patient 15 had been treated 3-years earlier for metastatic 
melanoma with lung involvement from a separate lesion on 
the left arm but was thought to be in remission. In view of the 
history she proceeded straight to excisional biopsy of the left 
breast nodule and pathology showed malignant melanoma. 
She received adjuvant chemotherapy and immunotherapy but 
developed lung metastases 3-years later. Following further 
oncological therapy the patient has been disease free for the 
last 9-years. Patient 16 had been treated with chemotherapy 
8-years previously for a cutaneous malignant melanoma of 
her left lower limb and was also thought to be in remission. 
She had both USS and mammogram investigations (U = 4, M 
= 4). Subsequent FNA and core biopsy confirmed malignant 
melanoma (Figure 3). Despite palliative radiotherapy, this 
patient died 7-weeks later from metastatic disease. 
Fig 3. Breast melanoma (H&E x 200) (Inset - Hmb45 
immunohistochemistry stain for melanoma). This field shows 
melanoma cells some of which are producing brown melanin 
pigment. The cells are HMB45 positive.© The Ulster Medical Society, 2009.
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Metastatic multiple myeloma 
Patient 17 (F, 71) presented with a 28-day history of a right-
sided breast lump. She had a history of multiple myeloma and 
left mastectomy 4-years earlier for a metastatic myelomatous 
deposit. Although mammography was indeterminate (M = 
3), ultrasound imaging was suspicious of malignancy (U = 
4).  Subsequent  FNA  and  core  biopsy  investigations  were 
indeterminate.  Excisional  biopsy  confirmed  metastatic 
multiple  myeloma  which  was  treated  with  adjuvant 
chemotherapy (melphalan in combination with prednisolone 
and allopurinol) (Figure 4). The patient died from metastatic 
disease 342 days later. 
Metastatic carcinoid tumour
Patient 18 (F, 52) was referred from the breast-screening 
department  with  an  abnormality  in  the  right  breast.  USS 
and  FNA  investigations  were  equivocal  and  suggested 
fibroadenosis.  Core  biopsy  suggested  invasive  ductal 
carcinoma  and  she  proceeded  to  WLE  and  ANC. 
Histopathology  analysis  confirmed  a  grade-1  carcinoid 
tumour without nodal involvement. She proceeded to a simple 
mastectomy and was subsequently referred to the regional 
neuroendocrine department. Although she had no clinical 
evidence of carcinoid syndrome, she was commenced on 
the somatostatin analogue lanreotide. She was subsequently 
referred  for  gastrointestinal  screening  where  a  primary 
carcinoid  tumour  was  detected  in  the  distal  small  bowel 
9-months following her initial breast surgery. A small bowel 
resection  was  then  performed  and  she  remains  well  on 
lanreotide with no evidence of carcinoid syndrome.
Metastatic renal cell carcinoma
Patient 19 (F, 63) presented with a seven-day history of a 
right-sided breast lump. Past medical history included left 
nephrectomy  for  renal  cell  carcinoma  4-years  previously 
and she had known bony metastases. Mammogram and USS 
were suspicious of malignancy (M = 4, U = 4). FNA showed 
malignant cells and core biopsy confirmed metastatic renal 
cell  carcinoma  (Figure  5). Wide  local  excision  and ANC 
was  performed  and  the  patient  received  chemotherapy. A 
subsequent CT scan revealed widespread metastases. She 
died 1128 days later.
DISCUSSION
We will discuss the various types of non-epithelial breast 
malignancies,  with  particular  emphasis  on  epidemiology, 
symptomatology,  investigation,  pathology,  and  current 
management strategies for each particular type, with reference 
to our own experience over the last 14-years.
Lymphoma
Epidemiology:  The  reported  incidence  of  primary  breast 
lymphoma (PBL) in the literature ranges from 0.04% to 0.5% 
for all breast malignancies. It is estimated that the breast is 
involved in less than 1% of all patients with non-Hodgkin’s 
lymphoma  and  approximately  1.7%  of  extra-nodal  non-
Hodgkin  lymphomas8-9.  Secondary  spread  of  lymphomas 
to the breast is reported to account for just 0.07% of all 
breast malignancies8. However, these secondary lymphomas 
comprise the largest group (17%) of tumours that metastasise 
to the breast8,10. Our experience was similar with an incidence 
of 0.13% for PBL and 0.08% for secondary breast lymphomas. 
The reported median age for primary and secondary breast 
lymphoma ranges from 51 to 61 years8,11. The patients in 
our study were slightly older (mean 70.4 and 65.3 years for 
primary and secondary lymphomas respectively).
Symptomatology:  Wiseman  and  Liao  defined  the  clinical 
criteria  for  the  diagnosis  of  PBL  where;  the  breast  is 
the  clinical  site  of  the  first  major  manifestation  of  the 
lymphoma,  there  is  no  history  of  previous  lymphoma  or 
widespread  lymphomatous  disease  elsewhere  and  that 
the  lymphoma  is  demonstrated  with  close  association  to   
breast  tissue  in  the  pathologic  specimen12.  They  also 
state that ipsilateral lymph nodes may be involved if they 
develop simultaneously with the primary breast tumour12. 
The PBL patients in our series presented in a common way 
with  a  painless  unilateral  breast  mass. Although  bilateral 
PBL  disease  has  also  been  reported,  we  did  not  identify 
any  such  cases  in  our  study9.  PBL  frequently  appears  as 
Fig 5. Metastatic renal cell carcinoma of breast (H&E x 200). This 
section shows the typical morphology of renal cell carcinoma with 
small pleomorphic nuclei, clear cytoplasm and a fine vascular 
background.
Fig 4. Multiple myeloma deposit right breast (H&E x 200). This 
field shows large atypical plasma cells many of which are showing 
immunoblastic differentiation with large central nucleoli.© The Ulster Medical Society, 2009.
Non-epithelial malignancies and metastatic tumours of the breast 109
www.ums.ac.uk
a  benign  or  less  suspicious  lesion  on  clinical  assessment 
even though some reports state that lymphomas are larger 
at diagnosis than carcinomas11,13-14. Skin changes or nipple 
discharge  are  uncommon13.  Previous  reports  document  a 
right-sided predominance. However, recent studies have not 
supported this and in our series there was equal involvement 
bilaterally8,11,13. Axillary lymph nodes are involved in 30-40% 
of cases.13 Only one patient in this series had palpable nodes 
(patient 8). The presence of B symptoms (fever, night sweats 
and weight loss) is uncommon9.
Investigation: Radiologically, Lyou et al described lymphomas 
as oval-shaped and high-density masses on mammography 
and as single and hypoechoic masses with circumscribed or 
microlobulated margins on ultrasonography15. The detection 
Table I: 
Clinical data for all 19 patients
No Age Sex Symptom Investigations
Mam      USS
Diagnostic 
(+/-therapeutic) 
procedure 
Pathological Diagnosis Treatment Current 
Status
Length of 
follow-up 
(days)
1 59 F L + + EB PBL C Alive
(recurrence 
2003)
2741
2 83 F L, P n/a n/a WLE PBL Palliative Dead 3248
3 63 F L + n/a WLE PBL Dx, C Alive 4589
4 86 F L n/a n/a EB PBL Palliative Dead 32
5 61 F SC + n/a WLE PBL C Alive; several 
recurrences
3150
6 79 F L n/a n/a CB SBL SM Dead 775
7 52 M L n/a n/a EB SBL C Dead  1045
8 65 F L, P + + FNA/CB SBL Dx, C Dead 133
9 58 F L, P + n/a FNA PBS 
(rhabdomyosarcoma)
SM+ANC, 
Dx, C,
Dead 553
10 65 M L + + SM PBS 
(dermatofibrosarcoma)
SM Alive 380
11 29 F P n/a - FNA / US-guided 
EB
PBS 
(angiosarcoma)
SM, Dx Alive 1415
12 69 F L  + n/a FNA/CB Metastatic liposarcoma 
from primary thigh lesion
Palliative C, 
Dx
Dead  679
13 61 F L n/a n/a L Metastatic 
leiomyosarcoma from 
primary retroperitoneal 
lesion
L- Alive, several 
recurrences
2980
14 59 M S n/a n/a EB Malignant Melanoma  EB+ANC; 
SM later
Alive 373
15 25 F L n/a n/a EB Metastatic malignant 
Melanoma,
EB, C, I Alive 4470
16 70 F L + + FNA/CB Metastatic malignant 
Melanoma
Palliative Dead 50
17 71 F L + + EB Metastatic multiple 
myeloma
EB, C Dead 342
18 52 F SC + - WLE Metastatic Carcinoid WLE+ANC - Alive 1210
19 63 F L + n/a FNA/CB Metastatic renal cell 
carcinoma
WLE +ANC, 
Dx
Dead 1128
(symptom: L = lump, P = pain, S = skin change, SC = screening detected abnormality; investigations: Mam = mammography, US = Ultrasound, n/a = 
not performed or result not available, + = abnormality detected, - = abnormality not detected; diagnostic (+/- therapeutic) procedure: WLE = wide local 
excision, SM = simple mastectomy, ANC = axillary node clearance, EB = excisional biopsy, L = lumpectomy, CB = core biopsy; Pathological diagnosis: 
PBL = primary breast lymphoma, SBL = secondary breast lymphoma, PBS = primary breast sarcoma, Treatment: Dx = radiotherapy, C = chemotherapy, I = 
immunotherapy).© The Ulster Medical Society, 2009.
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of PBL by screening mammography, as occurred in the case of 
patient 5, is rare14. The reported sensitivity of FNA cytology in 
breast lymphoma is approximately 90% and is most sensitive 
when combined with immunohistocytochemistry (IHC) or 
flow cytometry8. In addition to histological analysis, further 
radiological staging is recommended with CT imaging of the 
chest, abdomen and pelvis to detect any evidence of visceral 
or nodal dissemination8,9. 
Pathology: The most common histological type reported in 
the literature when primary and secondary cases are grouped 
together is diffuse large B-cell lymphoma which represents 
45%  to  90%  of  all  cases8.  Burkitt-type  lymphoma,  and 
mucosa-associated lymphoid tissue–type lymphoma have also 
been documented9. 
Treatment: In our series, surgical biopsy was required for 
diagnosis in the majority of patients and excision was part 
of treatment in several patients treated in the earlier part of 
the study period. In contrast to epithelial breast neoplasms, 
it  is  now  accepted  that  surgical  resection  is  usually  only 
indicated  for  diagnostic  purposes  in  PBL.  Jennings  et  al 
reported  that  mastectomy  conferred  no  improvement  in 
survival or recurrence risk11. They also reported that combined 
chemoradiotherapy improved survival and recurrence rates 
in both stage I (node negative) and stage II (node positive) 
patients11. CHOP is the standard chemotherapy regimen9,11. 
The  addition  of  the  monoclonal  antibody  rituximab  is 
occasionally indicated and had been used in the treatment of 
recurrent disease in Patient 5. 
Prognosis: Histological tumour grading and stage can be 
used to predict patient outcomes. The use of the International 
Prognostic Index which evaluates risk factors such as Ann 
Arbor stage, extranodal disease, elevated LDH levels and 
performance status on echocardiography is limited in PBL9,16. 
The  prognosis  for  PBL  is  generally  poor  with  improved 
survival in patients with low-grade disease. Reported five-
year survival rates in PBL are 78-89% for stage I patients 
and 50% for stage II11. Three of the five patients (60%; 2 
low-grade, 1 high-grade) with PBL in this series survived 
beyond five years.
Sarcoma
Epidemiology: Primary breast sarcomas (PBS) are reported 
to account for less than 0.1% of all breast malignancies7. 
The incidence of PBS in our series was 0.08%. Although 
PBS typically affects women in their forties or fifties, a wide 
age  range  has  been  reported  (24-81  years)7. The  average 
age of patients in this series was similar (mean age 50.7 
years). PBS occurs very rarely in men7. Radiotherapy has 
been  implicated  in  the  aetiology  of  some  sarcoma  types 
especially  angiosarcoma17,18.  No  cause  was  identified  for 
any of the patients in our series. Angiosarcoma of the breast 
accounted for 0.03% of all breast malignancies in this series, 
which compares with the 0.04% reported in the literature17. 
Angiosarcomas also occur in younger patients with an age 
range between 20 and 40 years (patient 11)17. 
Symptomatology:  PBS  most  commonly  presents  as  a 
painless breast lump7. Sarcomas tend to spread locally or 
haematogenously  and  do  not  usually  spread  to  regional 
lymph  nodes18.  Each  of  the  five  patients  included  in  this 
series had palpable breast lumps with no evidence of axillary 
lymphadenopathy.
Investigation: Radiologically, PBS are generally ill-defined 
lesions  without  calcification  and  may  be  mistaken  for 
fibroadenomas19.  A  combination  of  ultrasound  and  MRI 
has been recommended for investigation of angiosarcoma20. 
However, both modalities failed to detect an angiosarcoma 
in patient 11 from our series. Therefore, if clinical suspicion 
persists,  the  authors  recommend  further  pathological 
assessment even if these modalities appear normal. Although 
FNA cytology permits the diagnosis of sarcomatous lesions, it 
does not facilitate subtyping or tumour grade. Core-needle or 
excisional biopsies are therefore invariably required. 
Pathology:  Malignant  fibrous  histiocytoma,  fibrosarcoma, 
angiosarcoma,  stromal  sarcoma,  leiomyosarcoma  and 
liposarcoma  comprise  the  major  subtypes  of  breast 
sarcomas7,21,22.  Proportional  figures  of  each  subtype  vary 
between case series because of differences in classification. 
Treatment:  Excluding  angiosarcomas,  current  evidence 
suggests that PBS have a similar course to sarcomas arising at 
any other site21. Surgical resection remains the most important 
treatment factor influencing outcome23. All patients in our 
series underwent surgical resection apart from patient 12 who 
was known to have widespread metastatic disease which was 
treated with palliative chemoradiotherapy. Patient 9 had ANC 
in addition to resection as FNA and core biopsy respectively 
had  suggested  an  epithelial  malignancy.  McGowan  et  al 
showed  no  statistically  significant  cause-specific  survival 
difference between breast-conserving surgery and mastectomy 
if  negative  margins  were  achieved18. Wide  local  excision 
should be adequate in most cases as tumour multicentricity 
and  axillary  spread  is  rare18,21,22.  There  is  no  conclusive 
evidence that radiotherapy is beneficial in PBS. However as 
radiotherapy has been shown to be beneficial in the treatment 
of other sarcomas, adjuvant radiotherapy may be indicated 
for PBS patients with questionable or positive margins, high-
grade features and those that are larger in size22. The role of 
chemotherapy in the treatment of PBS is also unclear22. 
Prognosis: PBS is an aggressive tumour. Prognosis is based 
on  tumour  size  and  histological  grade7,21.  Other  reported 
prognostic indicators include the age of the patient, tumour 
subtype and the presence of positive margins7,23. Zelek et 
al  reported  overall  survival  rates  of  82%,  62%  and  36% 
for patients with grades one, two and three breast sarcomas 
respectively21. Angiosarcomas have been linked with a poorer 
prognosis21.
Metastatic Spread to the Breast
Epidemiology: Metastatic spread to the breast from primary 
tumours at other sites in the body is rare24. A retrospective 
review over a 16-year period showed that non-haematological 
metastases accounted for 0.2% of all breast malignancies 
treated24. There was a female predominance and the most 
frequent types of non-haematological tumours spreading to 
the  breast  were  malignant  melanoma  and  neuroendocrine 
tumours such as carcinoid25-27. Malignant melanoma of the 
breast skin, as shown in patient 14, accounts for less than 5% 
of all malignant melanomas whereas melanoma metastases 
to the breast, as demonstrated in patients 15 and 16, accounts 
for 1.2% of all malignant melanomas28,29. Carcinoid tumours © The Ulster Medical Society, 2009.
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in the breast may occur as metastases from a known carcinoid 
primary tumour, as the first presentation of a carcinoid tumour 
(patient 18), or as a primary carcinoid breast malignancy. 
Following a review of all documented cases in the literature, 
Upalakalin et al estimated that 41% of all carcinoid tumours 
in the breast were metastases from elsewhere27. There are 
only isolated case reports documenting renal cell carcinoma 
metastasising to the breast. Although metastases were present 
in approximately 30% of patients with renal cell carcinoma, 
the breast was rarely involved30. As overall survival from 
metastatic disease improves, the incidence of secondary breast 
malignancies is likely to increase in number.
Symptomatology: The  majority  of  patients  have  a  known 
primary tumour. However, some patients will present with 
occult  primary  disease  where  the  breast  metastases  are 
the first manifestation of the disease24,31. Patient 18 in this 
series presented with metastatic carcinoid of the breast and 
subsequent investigations identified a small bowel carcinoid. 
In the review of metastases from a variety of different primary 
sites, Vaughan et al reported an average time between the 
diagnosis of the initial primary malignancy and development 
of a metastasis to the breast of 60.9 months24. We identified 
a similar time interval for patients with non-haematological 
breast metastases (Patients 12, 13, 15, 16, 18, 19) of 49.7 
months (0-102 months). Metastases to the breast are usually 
mobile,  well-demarcated  and  firm24,31.  Skin  changes  or 
mastalgia  are  unusual  but  axillary  lymphadenopathy  is 
often seen6,32. Clinical differentiation between metastases to 
the breast and primary cancers is difficult26. In melanoma, 
the patient will usually be premenopausal and have had a 
primary lesion on the upper body28. The presence of clinically 
significant extraosseus features in myelomatous metastases 
occur in less than 5% of cases and usually signifies aggressive 
disease26. Carcinoid  syndrome  is  usually  not  a  feature  of 
carcinoid tumours of the breast. If a patient with a breast 
lump also has symptoms of carcinoid syndrome then the lump 
should be biopsied to exclude metastatic carcinoid from a 
primary elsewhere27.
Investigation:  These  malignancies  show  a  wide  range  of 
mammographic  and  ultrasound  appearances31. They  often 
appear  as  round,  well-circumscribed  lesions  without  the 
microcalcifications of primary epithelial malignancies and 
may  be  misinterpreted  as  benign  lesions24,31. Ultrasound 
commonly shows hypoechoic masses31. FNA or ultrasound 
guided core biopsy is advised to diagnose breast lumps that 
either clinically or radiographically are not typical of primary 
breast tumours6,33. 
Pathology:  Vergier  et  al  reported  that  histological 
characteristics of metastases included the presence of well-
circumscribed tumours with multiple satellite foci, an absence 
of an intraductal component or the presence of lymphatic 
emboli25. Histologically, carcinoid tumours of the breast may 
be misdiagnosed as epithelial malignancies even when the 
patient has a known history of a carcinoid tumour elsewhere27. 
An accurate diagnosis of a breast metastasis is important to 
avoid unnecessary mastectomy and to implement appropriate 
investigations  for  the  primary  lesion  and  to  commence 
systemic chemotherapy if indicated 24. 
Treatment:  Deciding  which  treatment  is  most  appropriate 
can be challenging in these cases as it is often difficult to 
predict if and when a patient will develop complications of 
metastatic disease. There is little information in the literature 
regarding best practice. In the study by Vaughan et al, 61% 
of patients underwent some form of resection but only 22% 
of these patients had their resection for a curative intent24. 
Surgical debulking or excision for palliative purposes may 
be  appropriate  in  widely  metastatic  disease.  In  cases  of 
melanoma  of  the  breast  without  multiple  deposits,  WLE 
or  quandrantectomy  is  acceptable29.  For  solitary  multiple 
myeloma of the breast, a localised biopsy with radiotherapy 
has  been  recommended,  with  chemotherapy  reserved  for 
disseminated disease26. With regards to primary carcinoid 
tumours of the breast, modified radical mastectomy or breast 
conserving  surgery  with ANC  and  radiotherapy  has  been 
advised27. Patients with metastatic carcinoid tumours should 
undergo lumpectomy alone27.
Prognosis: There is limited data in the literature regarding 
the  prognosis  of  these  patients  but  breast  metastases 
usually indicate disseminated metastatic disease and a poor 
prognosis28,34. As new systemic treatments emerge however 
survival rates may improve. Vaughan et al  reported a mean 
survival time of 17.8 months following the diagnosis of a 
breast  metastasis  of  non-haematological  origin24.  Survival 
was similar regardless of primary site apart from patients 
with medullary thyroid cancer who survived for longer. In this 
study, three patients with non-haematological metastases to 
the breast died (patients 12, 16 and 19) with a mean survival 
time of 619 days (approximately 20 months). Median survival 
in a review of 27 cases of melanoma metastases to the breast 
was 12.9 months28.
CONCLUSION
Non-epithelial malignancies of the breast include primary 
breast tumours such as lymphoma and sarcoma and metastatic 
deposits from primary tumours elsewhere in the body. They 
are  rare  cancers  with  a  female  predominance.  Nineteen 
patients were identified in this 14-year retrospective review 
accounting  for  0.49%  of  all  breast  malignancies  treated. 
A  thorough  history  and  triple  assessment  is  required  to 
correctly identify these cancers as clinical and radiological 
differentiation from the more common epithelial cancers is 
often challenging. Primary breast sarcomas require surgical 
excision and adjuvant therapy whereas lymphomas can be 
predominantly managed with oncological therapies alone. 
Management of metastases to the breast depends on a number 
of factors including tumour type and extent of metastatic 
disease.
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